Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/BCMA CAR-T in Refractory Autoimmune Diseases
NCT07490951Recruiting
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of CD19/BCMA-targeted CAR-T lentiviral vector in autoimmune disease. Primary endpoints: Incidence of adverse events at 24 months and Maximal Tolerated Dose at 28 days. Started Mar 2026; status: recruiting.
02
Drugs
CD19/BCMA-targeted CAR-T lentiviral vector
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT07490951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490951.